RO4929097 After Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

Inclusion Criteria: * Patients must have a diagnosis of multiple myeloma as defined below with staging based on the International Staging System: * Multiple myeloma - all three required (Note: these criteria identify stage 1B and stages II and IIIA/B myeloma by Durie/Salmon stage; stage 1A becomes smoldering or indolent myeloma): * Monoclonal plasma cells in the bone marrow ≥ 10% and/or presence of a biopsy-proven plasmacytoma * Monoclonal protein present in the serum and/or urine (if no monoclonal protein is detected \[non-secretory disease\], then \>= 30% monoclonal bone marrow plasma cells and/or biopsy-proven plasmacytoma is required) * Myeloma-related organ dysfunction (1 or more) (a variety of other types of end organ dysfunctions can occasionally occur and lead to a need for therapy; such dysfunction is sufficient to support classification as myeloma if proven to be myeloma related): * Calcium elevation in the blood (serum calcium \> 10.5 mg/L or upper limit of normal) * Renal insufficiency (serum creatinine \> 2mg/dL) * Anemia (hemoglobin \< 10 g/dL or 2 g \< normal) * Lytic bone lesions or osteoporosis (if a solitary \[biopsy-proven\] plasmacytoma or osteoporosis alone \[without fractures\] are the sole defining criteria, then \> 30% plasma cells are required in the bone marrow) * Patients must have measurable disease * Patients with non-secretory multiple myeloma will be eligible only if the baseline serum free light chai…